Literature DB >> 30443859

Comparison of breast-conserving surgery and mastectomy in early breast cancer using observational data revisited: a propensity score-matched analysis.

Kai Chen1,2, Zihao Pan1,2,3, Liling Zhu1,2, Tingting Hu1,2, Min Peng1,2, Weijuan Jia1,2, Fengxi Su1,2, Shunrong Li4,5, Erwei Song6,7,8.   

Abstract

Recent observational studies showed that breast-conserving surgery (BCS) resulted in superior survival compared to mastectomy in breast cancer patients. This study compared the clinical outcomes of BCS and mastectomy using propensity score (PS) matching analysis, which had advantages over conventional methods in reducing bias. Nonmetastatic breast cancer patients who underwent BCS and mastectomy were matched 1:1 based on their PS. We used the Kaplan-Meier method and Cox-regression model to estimate the treatment effects. A total of 2,866 patients with a median follow-up time of 67 months were included in the original study population. Although the mastectomy cohort (N=1,219) had more advanced disease compared to the BCS cohort (N=1,647), LRFS was similar between the two groups (93.8% vs. 92.4%, P>0.05). BCS (vs. mastectomy) was associated with improved DFS (73.8% vs. 58.7%, P<0.01) and CSS (91% vs. 78.2%, P<0.01) in the original population. In the PS-matched population (N=1,668), clinicopathological features were equally distributed between the two cohorts. BCS (vs. mastectomy) was not associated with improved DFS (70.7% vs. 66.9%, P>0.05) or CSS (87.5% vs. 84.9%, P>0.05). We found that PS methods reduce bias when estimating treatment effects using observational data. BCS and mastectomy show equivalent outcomes in nonmetastatic breast cancer patients.

Entities:  

Keywords:  breast cancer; breast-conserving surgery; mastectomy; propensity score; survival

Mesh:

Year:  2018        PMID: 30443859     DOI: 10.1007/s11427-018-9396-x

Source DB:  PubMed          Journal:  Sci China Life Sci        ISSN: 1674-7305            Impact factor:   6.038


  3 in total

1.  The prognostic and predictive value of the 8th American Joint Committee on Cancer (AJCC) staging system among early breast cancer patients aged <50 years.

Authors:  Jun Wang; Chen-Lu Lian; Ping Zhou; Jian Lei; Li Hua; Zhen-Yu He; San-Gang Wu
Journal:  Gland Surg       Date:  2021-01

Review 2.  Triple-negative breast cancer: new treatment strategies in the era of precision medicine.

Authors:  Song-Yang Wu; Hai Wang; Zhi-Ming Shao; Yi-Zhou Jiang
Journal:  Sci China Life Sci       Date:  2020-08-11       Impact factor: 6.038

3.  Neoadjuvant systemic therapy does not compromise local control after breast-conserving surgery: a single-center, propensity score matching study in China.

Authors:  Fan Yang; Si-Yu Wu; Miao Mo; Qin Xiao; Xia Yang; Ying-Ying Liu; Jian-Wei Li; Zhi-Ming Shao; Guang-Yu Liu
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.